Mortality from PROWESS and ENHANCE based on end-of-infusion PC levels by categories

The protein C (PC) categories were normal (> 80%), deficient (41% to 80%), and severely deficient (< 40%). The number in each column is the total number of patients in each category. Patients were included if they had a baseline PC measure. Day 4 PC was classified as end of infusion. If day 4 measurement was not available, last observation carried forward values were used for classification. These data were reported by Vangerow and coworkers [42]. ENHANCE, Extended Evaluation of Recombinant Activated Protein C; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.<p><b>Copyright information:</b></p><p>Taken from "Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)"</p><p>http://ccforum.com/content/12/2/R45</p><p>Critical Care 2008;12(2):R45-R45.</p><p>Published online 4 Apr 2008</p><p>PMCID:PMC2447591.</p><p></p

Illustration of 28-day mortality RR reduction (DrotAA versus placebo) for each potential biomarker at baseline

The point estimates of relative risk (RR) for death in patients at lower risk and higher risk, based on statistically defined cut-offs (shown in Table 2), are indicated by open ovals and solid ovals, respectively; 95% confidence intervals (CIs) are indicated by horizontal lines. Only protein C (PC) was significantly (< 0.05) different between the two risk groups, as indicated by the least overlap in CIs, indicating a differential benefit. values were determined using Breslow-Day tests. AT, antithrombin; CI, confidence interval; DrotAA, drotrecogin alfa (activated); IL, interleukin; PT, prothrombin time; SOFA, Sequential Organ Failure Assessment.<p><b>Copyright information:</b></p><p>Taken from "Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)"</p><p>http://ccforum.com/content/12/2/R45</p><p>Critical Care 2008;12(2):R45-R45.</p><p>Published online 4 Apr 2008</p><p>PMCID:PMC2447591.</p><p></p

Additional file 2: of The impairment of small nerve fibers in severe sepsis and septic shock

Nerve conduction studies. Amplitudes of compound potentials in motor and sensory nerves are considerably decreased, and conduction velocity is marginally impaired. Note that nerve conduction studies detect critical illness polyneuropathy early in the course of sepsis, but amplitudes do not change considerably over the course of the disease. Horizontal lines show the normative values of the measurements. (PDF 340 kb

Additional file 1: of The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial

Supplementary results. (PDF 5376 kb